Chiara Molinelli
University of Genoa
40 Papers
3 Citations
Chiara Molinelli is an academic researcher from University of Genoa. The author has contributed to research in topics: Breast cancer & Internal medicine. The author has an hindex of 4, co-authored 10 publications.
Chat about Author
Papers
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
Mattia Garutti,Gaia Griguolo,Andrea Botticelli,Giulia Buzzatti,Carmine De Angelis,Lorenzo Gerratana,Chiara Molinelli,Vincenzo Adamo,Giampaolo Bianchini,Laura Biganzoli,Giuseppe Curigliano,Michelino De Laurentiis,Alessandra Fabi,Antonio Frassoldati,Alessandra Gennari,Caterina Marchiò,Francesco Perrone,Giuseppe Viale,Claudio Zamagni,Alberto Zambelli,Lucia Del Mastro,Sabino De Placido,Valentina Guarneri,Paolo Marchetti,Fabio Puglisi +24 more
TL;DR: The IRIDE (high risk definition in breast cancer) working group was established with the aim of reviewing evidence from the literature to synthesize the current relevant features that predict hormone-positive/her2−negative early breast cancer relapse, and may guide clinicians in the practical management of hormone- positive/HER2− negative early breast cancers.
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study.
Eva Blondeaux,Matteo Lambertini,Andrea Michelotti,Benedetta Conte,Marco Benasso,Chiara Dellepiane,Claudia Bighin,S. Pastorino,Alessia Levaggi,Alessia D’ Alonzo,Francesca Poggio,Giulia Buzzatti,Chiara Molinelli,Piero Fregatti,Sergio Bertoglio,Francesco Boccardo,Lucia Del Mastro +16 more
TL;DR: In the MIG-1 trial as discussed by the authors, node-positive and high-risk node-negative breast cancer patients were randomised to receive six cycles of adjuvant fluorouracil, epirubicin and cyclophosphamide regimen administered every 3 or 2 weeks.
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)
Claudio Vernieri,Federico Nichetti,Luca Lalli,Luca Moscetti,Carlo Alberto Giorgi,Gaia Griguolo,Antonio Marra,Giovanni Randon,Carmen G. Rea,Francesca Ligorio,Simone Scagnoli,Claudia De Angelis,Chiara Molinelli,A. Fabbri,Emanuela Ferraro,Dario Trapani,Andrea Milani,Elisa Agostinetto,Ottavia Bernocchi,Giovanna Catania,Amelia Vantaggiato,Michela Palleschi,Anna Moretti,Debora Basile,Marika Cinausero,Arta Ajazi,Lorenzo Castagnoli,Salvatore Lo Vullo,Lorenzo Gerratana,Fabio Puglisi,Nicla La Verde,Grazia Arpino,Andrea Rocca,Mariangela Ciccarese,Rebecca Pedersini,Alessandra Fabi,Daniele Generali,Agnese Losurdo,Filippo Montemurro,Giuseppe Curigliano,Lucia Del Mastro,Andrea Michelotti,Enrico Cortesi,Valentina Guarneri,Giancarlo Pruneri,Luigi Mariani,Filippo de Braud +46 more
TL;DR: In this paper, the impact of baseline and on-treatment blood glucose levels on progression-free survival (PFS) in patients with HR+/HER2− aBC treated with everolimus-exemestane was investigated.
Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis
Diogo Martins-Branco,G. Nader-Marta,Chiara Molinelli,Lieveke Ameye,Marianne Paesmans,Michail Ignatiadis,Philippe Aftimos,Roberto Salgado,Evandro de Azambuja +8 more
TL;DR: High Ki-67 index after NET is associated with worse survival outcomes, even after a short course of NET, emphasising the prognostic value of this biomarker in women with ER-positive/HER2-negative early breast cancer.
6
DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer.
Véronique Debien,Virginie S. Adam,E. Coart,Elisa Agostinetto,Theodora Goulioti,Chiara Molinelli,Amal Arahmani,Gabriele Zoppoli,Martine Piccart +8 more
TL;DR: DECRESCENDO (NCT04675827) is a large, multicenter, single-arm phase II trial in patients with HR-negative, HER2-positive, node-negative early BC evaluating a neoadjuvant pertuzumab and trastuzumAB fixed-dose combination administered subcutaneously plus taxane-based chemotherapy followed by adjuvant treatment, adapted according to response to neoadedjuvant therapy.
4